Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • oral myeloma therapy

    - PMLiVE

    ViiV Healthcare receives NICE recommendation for HIV prevention therapy

    The treatment is the first and only long-acting HIV prevention option available on the NHS in England and Wales

    - PMLiVE

    Pfizer’s Lorviqua recommended by NICE for lung cancer

    Lung cancer is the leading cause of cancer-related deaths worldwide

    - PMLiVE

    BMS, Takeda and Astex join AI training consortium

    The initiative focuses on training AI models to aid in drug discovery and development

    - PMLiVE

    EMA reaffirms guidance on paracetamol use during pregnancy

    The guidance follows recent US comments about a possible link to autism

    - PMLiVE

    Johnson & Johnson seeks first EMA approval for icotrokinra for plaque psoriasis

    Icotrokinra is a first-in-class, once-daily tablet for moderate-to-severe plaque psoriasis

    - PMLiVE

    EMA orphan drug designation given to ReAlta for graft-versus-host disease therapy

    This follows preliminary results from the company's ongoing phase 2 trial

    - PMLiVE

    NICE recommends ALK’s immunotherapy to target underlying cause of hay fever

    An estimated 26,800 people in England with moderate-to-severe cases could benefit from Itulazax

    - PMLiVE

    NICE recommends BeOne’s Brukinsa to treat mantle cell lymphoma on NHS

    Approximately 600 people are affected by the form of non-Hodgkin lymphoma every year in the UK

    - PMLiVE

    Novartis’ Kisqali recommended by NICE to treat broad early breast cancer population

    The drug was previously available only for patients whose cancer had spread to nearby lymph nodes

    - PMLiVE

    Vertex’s triple combination cystic fibrosis therapy Alyftrek recommended by NICE

    The rare inherited disease affects approximately 11,000 people in the UK

    - PMLiVE

    Boehringer’s Spevigo recommended by NICE for generalised pustular psoriasis

    The rare form of psoriasis can lead to serious complications such as sepsis and heart failure

    - PMLiVE

    Takeda receives EC approval for Adcetris combination in Hodgkin lymphoma

    The decision marks the second approval for an Adcetris-based regimen for front-line Hodgkin lymphoma

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links